Thrivent Financial for Lutherans
KYMR icon

Thrivent Financial for Lutherans’s Kymera Therapeutics KYMR Stock Holding History

Thrivent Financial for Lutherans’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,617
Closed -$313K – 2579
2024
Q3 		$313K Buy
+6,617
New +$292K ﹤0.01% 2386
2022
Q2 		– Sell
-8,096
Closed -$343K – 2481
2022
Q1 		$343K Buy
+8,096
New +$342K ﹤0.01% 2313

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Thrivent Financial for Lutherans's KYMR Position: Q4 2024 in Review

Thrivent Financial for Lutherans sold out of Kymera Therapeutics (KYMR) in Q4 2024, closing a stake of 6,617 shares — an estimated $313K sold.

Thrivent Financial for Lutherans first reported a position in KYMR in Q1 2022 and held it in 2 quarters. The position peaked at $343K in Q1 2022. 180 funds tracked by Wall St. Rank hold KYMR as of Q4 2024.

  • Thrivent Financial for Lutherans reported no remaining Kymera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 6,617 Kymera Therapeutics shares in Q4 2024, an estimated $313K.
  • Thrivent Financial for Lutherans first reported a position in Kymera Therapeutics in Q1 2022 and held it in 2 quarters.
  • Thrivent Financial for Lutherans's Kymera Therapeutics position peaked at $343K in Q1 2022.
  • 180 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2024.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2024, filed 10 Feb 2025.